Secoisolariciresinol diglucoside (SDG)
Clinical trialMechanism of Action
Research Notes
SDG is the primary lignan in flaxseed, present at concentrations 75-800 times higher than other dietary sources. Clinical trials demonstrate cholesterol-lowering effects, blood pressure reduction, and potential breast cancer risk reduction. The LIGNANS trial showed significant reduction in hot flash frequency in postmenopausal women. Enterolactone levels correlate inversely with breast cancer risk in epidemiological studies.
Found In 1 Herb
3D Molecular Structure
Secoisolariciresinol diglucoside (SDG)
Representative pattern: C₁₁H₁₄O₆
Live Research
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare practitioner before using any herbal product.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This content is for educational purposes only and is not a substitute for professional medical advice.
